Your session is about to expire
← Back to Search
SABR for Metastatic Prostate Cancer (ANCHORProstate Trial)
Phase 2
Recruiting
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trialwill investigate if SABR treatment helps men with metastatic prostate cancer live longer. 80 patients will be randomly selected to receive this experimental treatment.
Who is the study for?
This trial is for men with metastatic prostate cancer who are part of the PERa registry and have shown the best possible response to standard treatments, as seen by stable PSA levels. They should be able to perform daily activities (ECOG 0-2) and have a PSA greater than 0.2 ng/mL. Only those with 1-5 areas of cancer detectable on PSMA-PET scans that can be targeted by SABR will qualify.
What is being tested?
The ANCHOR-Prostate trial is testing whether adding a type of precise radiation therapy called SABR (Stereotactic Ablative Radiotherapy) after maximum response from usual drug treatments can help control prostate cancer better. The main goal is to see if patients remain free from disease progression one year after treatment.
What are the potential side effects?
While specific side effects are not listed here, SABR commonly includes risks such as fatigue, skin reactions in treated areas, urinary issues like increased frequency or discomfort, bowel changes including diarrhea or rectal bleeding, and potential impacts on sexual function.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
FFS
Secondary study objectives
Toxicity
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: SABR consolidationExperimental Treatment1 Intervention
Group II: Control - no SABR consolidationActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SABR
2012
Completed Phase 2
~110
Find a Location
Who is running the clinical trial?
Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
380 Previous Clinical Trials
131,509 Total Patients Enrolled
5 Trials studying Prostate Cancer
2,109 Patients Enrolled for Prostate Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have 1-5 areas of cancer visible on a PSMA-PET scan that can be treated with targeted radiation.Not applicable.I can take care of myself and perform daily activities.My prostate cancer has spread, and my PSA levels have been stable after starting standard treatment.
Research Study Groups:
This trial has the following groups:- Group 1: Control - no SABR consolidation
- Group 2: SABR consolidation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.